Loading…
Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
Introduction Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy cost per responder and number needed to treat (NNT) of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg to achieve glycemic, weight loss, and composite treatment...
Saved in:
| Published in: | Diabetes therapy 2023-12, Vol.14 (12), p.2045-2055 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c493t-dfaa847ec7b14d6ee2a2c6635a79b202c0848e3119a3c2c32e9bc0f0c38eee6e3 |
| container_end_page | 2055 |
| container_issue | 12 |
| container_start_page | 2045 |
| container_title | Diabetes therapy |
| container_volume | 14 |
| creator | Mody, Reema R. Meyer, Kellie L. Ward, Jennifer M. O’Day, Ken B. |
| description | Introduction
Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy cost per responder and number needed to treat (NNT) of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg to achieve glycemic, weight loss, and composite treatment endpoints in patients with T2D in the United States.
Methods
The proportions of patients achieving glycemic, weight loss, and composite treatment endpoints were obtained from the phase 3 SURPASS-2 randomized clinical trial which compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg. Annual pharmacy costs were calculated using 2022 wholesale acquisition costs. Cost per responder and NNT were calculated along with 95% confidence intervals and tests for statistical significance (
P
≤ 0.05).
Results
Tirzepatide had a lower cost per responder to achieve glycated hemoglobin A1c (HbA1c) endpoints of ≤ 6.5% (10 mg and 15 mg doses) and |
| doi_str_mv | 10.1007/s13300-023-01470-w |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10597950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A770254159</galeid><sourcerecordid>A770254159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-dfaa847ec7b14d6ee2a2c6635a79b202c0848e3119a3c2c32e9bc0f0c38eee6e3</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEolXpC7BAltiwSfFPEscrNBqgIFUFqVO2luPcZFwlzmA7HZWn6Y734MlwmumUIkSyiHX9nXNz7ZMkLwk-IRjzt54whnGKKUsxyThOt0-SQ1IWIi1EQZ7u1zk7SI69v8LxYUIIQp4nB4xzjjkuDpOfy8EHtAGHvqpgwAa00GsD18a2aOVAhX6qrZRrIXikbI3Ox76K-DlADTUKw4yhrQlrtDLuB2yiUQ3oGzg_enQBvWq78a5Eft32LTL2vpffqW42gCh6b1QFAfwEhDWgS2tC7HARVCy-SJ41qvNwvPseJZcfP6yWn9KzL6efl4uzVGeChbRulCozDppXJKsLAKqoLgqWKy4qiqnGZVYCI0QopqlmFESlcYM1KwGgAHaUvJt9N2PVQ63jXzrVyY0zvXI3clBGPt6xZi3b4VoSnAsuchwd3uwc3PB9BB9kb7yGrlMWhtFLWnIsBM1KEdHXf6FXw-hsnE9SwUqS5TzDD1SrOpDGNkNsrCdTuYjXSPOM5JPXyT-o-NbQGz1YaEysPxLQWaDd4L2DZj8kwXKKmJwjJmPE5F3E5DaKXv15PHvJfaAiwGbAxy3bgnsY6T-2vwFZ_96I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2938145740</pqid></control><display><type>article</type><title>Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States</title><source>Nexis UK</source><source>PubMed Central Free</source><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><source>Publicly Available Content (ProQuest)</source><creator>Mody, Reema R. ; Meyer, Kellie L. ; Ward, Jennifer M. ; O’Day, Ken B.</creator><creatorcontrib>Mody, Reema R. ; Meyer, Kellie L. ; Ward, Jennifer M. ; O’Day, Ken B.</creatorcontrib><description>Introduction
Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy cost per responder and number needed to treat (NNT) of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg to achieve glycemic, weight loss, and composite treatment endpoints in patients with T2D in the United States.
Methods
The proportions of patients achieving glycemic, weight loss, and composite treatment endpoints were obtained from the phase 3 SURPASS-2 randomized clinical trial which compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg. Annual pharmacy costs were calculated using 2022 wholesale acquisition costs. Cost per responder and NNT were calculated along with 95% confidence intervals and tests for statistical significance (
P
≤ 0.05).
Results
Tirzepatide had a lower cost per responder to achieve glycated hemoglobin A1c (HbA1c) endpoints of ≤ 6.5% (10 mg and 15 mg doses) and < 5.7% (all doses) and weight loss endpoints of ≥ 5% (10 mg and 15 mg doses), ≥ 10% (all doses), and ≥ 15% (all doses). The cost per responder to achieve HbA1c < 7% (all doses of tirzepatide) and ≤ 6.5% (5 mg tirzepatide) were not statistically significantly different between tirzepatide and semaglutide 1 mg. The cost per patient to achieve the composite endpoints (HbA1c < 7.0%, ≤ 6.5%, or < 5.7%/weight loss ≥ 10%/no hypoglycemia) was statistically significantly lower for all doses of tirzepatide than for semaglutide 1 mg. The NNTs for all doses of tirzepatide were statistically significantly lower than that for semaglutide 1 mg to achieve all individual and composite endpoints, with the exception of the 5 mg dose for HbA1c < 7.0% and HbA1c ≤ 6.5%, where tirzepatide had numerically lower NNTs that were not statistically significant.
Conclusion
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that may offer the potential to achieve stringent glycemic goals, weight loss targets, and composite treatment goals at a lower cost per responder compared to semaglutide 1 mg among people with T2D.</description><identifier>ISSN: 1869-6953</identifier><identifier>EISSN: 1869-6961</identifier><identifier>DOI: 10.1007/s13300-023-01470-w</identifier><identifier>PMID: 37770706</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Antidiabetics ; Cardiology ; Comparative analysis ; Dextrose ; Diabetes ; Diabetes therapy ; Drugstores ; Economic aspects ; Endocrinology ; GLP-1 receptor agonists ; Glucose ; Glycosylated hemoglobin ; Hypoglycemia ; Insulin ; Internal Medicine ; Liraglutide ; Medicine ; Medicine & Public Health ; Original Research ; Patient compliance ; Patients ; Pharmaceutical industry ; Pharmacy ; Type 2 diabetes</subject><ispartof>Diabetes therapy, 2023-12, Vol.14 (12), p.2045-2055</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>COPYRIGHT 2023 Springer</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c493t-dfaa847ec7b14d6ee2a2c6635a79b202c0848e3119a3c2c32e9bc0f0c38eee6e3</cites><orcidid>0000-0002-3442-1714</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2938145740/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2938145740?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37770706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mody, Reema R.</creatorcontrib><creatorcontrib>Meyer, Kellie L.</creatorcontrib><creatorcontrib>Ward, Jennifer M.</creatorcontrib><creatorcontrib>O’Day, Ken B.</creatorcontrib><title>Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States</title><title>Diabetes therapy</title><addtitle>Diabetes Ther</addtitle><addtitle>Diabetes Ther</addtitle><description>Introduction
Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy cost per responder and number needed to treat (NNT) of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg to achieve glycemic, weight loss, and composite treatment endpoints in patients with T2D in the United States.
Methods
The proportions of patients achieving glycemic, weight loss, and composite treatment endpoints were obtained from the phase 3 SURPASS-2 randomized clinical trial which compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg. Annual pharmacy costs were calculated using 2022 wholesale acquisition costs. Cost per responder and NNT were calculated along with 95% confidence intervals and tests for statistical significance (
P
≤ 0.05).
Results
Tirzepatide had a lower cost per responder to achieve glycated hemoglobin A1c (HbA1c) endpoints of ≤ 6.5% (10 mg and 15 mg doses) and < 5.7% (all doses) and weight loss endpoints of ≥ 5% (10 mg and 15 mg doses), ≥ 10% (all doses), and ≥ 15% (all doses). The cost per responder to achieve HbA1c < 7% (all doses of tirzepatide) and ≤ 6.5% (5 mg tirzepatide) were not statistically significantly different between tirzepatide and semaglutide 1 mg. The cost per patient to achieve the composite endpoints (HbA1c < 7.0%, ≤ 6.5%, or < 5.7%/weight loss ≥ 10%/no hypoglycemia) was statistically significantly lower for all doses of tirzepatide than for semaglutide 1 mg. The NNTs for all doses of tirzepatide were statistically significantly lower than that for semaglutide 1 mg to achieve all individual and composite endpoints, with the exception of the 5 mg dose for HbA1c < 7.0% and HbA1c ≤ 6.5%, where tirzepatide had numerically lower NNTs that were not statistically significant.
Conclusion
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that may offer the potential to achieve stringent glycemic goals, weight loss targets, and composite treatment goals at a lower cost per responder compared to semaglutide 1 mg among people with T2D.</description><subject>Antidiabetics</subject><subject>Cardiology</subject><subject>Comparative analysis</subject><subject>Dextrose</subject><subject>Diabetes</subject><subject>Diabetes therapy</subject><subject>Drugstores</subject><subject>Economic aspects</subject><subject>Endocrinology</subject><subject>GLP-1 receptor agonists</subject><subject>Glucose</subject><subject>Glycosylated hemoglobin</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Internal Medicine</subject><subject>Liraglutide</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Research</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pharmacy</subject><subject>Type 2 diabetes</subject><issn>1869-6953</issn><issn>1869-6961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9ks1u1DAUhSMEolXpC7BAltiwSfFPEscrNBqgIFUFqVO2luPcZFwlzmA7HZWn6Y734MlwmumUIkSyiHX9nXNz7ZMkLwk-IRjzt54whnGKKUsxyThOt0-SQ1IWIi1EQZ7u1zk7SI69v8LxYUIIQp4nB4xzjjkuDpOfy8EHtAGHvqpgwAa00GsD18a2aOVAhX6qrZRrIXikbI3Ox76K-DlADTUKw4yhrQlrtDLuB2yiUQ3oGzg_enQBvWq78a5Eft32LTL2vpffqW42gCh6b1QFAfwEhDWgS2tC7HARVCy-SJ41qvNwvPseJZcfP6yWn9KzL6efl4uzVGeChbRulCozDppXJKsLAKqoLgqWKy4qiqnGZVYCI0QopqlmFESlcYM1KwGgAHaUvJt9N2PVQ63jXzrVyY0zvXI3clBGPt6xZi3b4VoSnAsuchwd3uwc3PB9BB9kb7yGrlMWhtFLWnIsBM1KEdHXf6FXw-hsnE9SwUqS5TzDD1SrOpDGNkNsrCdTuYjXSPOM5JPXyT-o-NbQGz1YaEysPxLQWaDd4L2DZj8kwXKKmJwjJmPE5F3E5DaKXv15PHvJfaAiwGbAxy3bgnsY6T-2vwFZ_96I</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Mody, Reema R.</creator><creator>Meyer, Kellie L.</creator><creator>Ward, Jennifer M.</creator><creator>O’Day, Ken B.</creator><general>Springer Healthcare</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3442-1714</orcidid></search><sort><creationdate>20231201</creationdate><title>Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States</title><author>Mody, Reema R. ; Meyer, Kellie L. ; Ward, Jennifer M. ; O’Day, Ken B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-dfaa847ec7b14d6ee2a2c6635a79b202c0848e3119a3c2c32e9bc0f0c38eee6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antidiabetics</topic><topic>Cardiology</topic><topic>Comparative analysis</topic><topic>Dextrose</topic><topic>Diabetes</topic><topic>Diabetes therapy</topic><topic>Drugstores</topic><topic>Economic aspects</topic><topic>Endocrinology</topic><topic>GLP-1 receptor agonists</topic><topic>Glucose</topic><topic>Glycosylated hemoglobin</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Internal Medicine</topic><topic>Liraglutide</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Research</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pharmacy</topic><topic>Type 2 diabetes</topic><toplevel>online_resources</toplevel><creatorcontrib>Mody, Reema R.</creatorcontrib><creatorcontrib>Meyer, Kellie L.</creatorcontrib><creatorcontrib>Ward, Jennifer M.</creatorcontrib><creatorcontrib>O’Day, Ken B.</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mody, Reema R.</au><au>Meyer, Kellie L.</au><au>Ward, Jennifer M.</au><au>O’Day, Ken B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States</atitle><jtitle>Diabetes therapy</jtitle><stitle>Diabetes Ther</stitle><addtitle>Diabetes Ther</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>14</volume><issue>12</issue><spage>2045</spage><epage>2055</epage><pages>2045-2055</pages><issn>1869-6953</issn><eissn>1869-6961</eissn><abstract>Introduction
Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy cost per responder and number needed to treat (NNT) of tirzepatide 5 mg, 10 mg, and 15 mg versus semaglutide 1 mg to achieve glycemic, weight loss, and composite treatment endpoints in patients with T2D in the United States.
Methods
The proportions of patients achieving glycemic, weight loss, and composite treatment endpoints were obtained from the phase 3 SURPASS-2 randomized clinical trial which compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg. Annual pharmacy costs were calculated using 2022 wholesale acquisition costs. Cost per responder and NNT were calculated along with 95% confidence intervals and tests for statistical significance (
P
≤ 0.05).
Results
Tirzepatide had a lower cost per responder to achieve glycated hemoglobin A1c (HbA1c) endpoints of ≤ 6.5% (10 mg and 15 mg doses) and < 5.7% (all doses) and weight loss endpoints of ≥ 5% (10 mg and 15 mg doses), ≥ 10% (all doses), and ≥ 15% (all doses). The cost per responder to achieve HbA1c < 7% (all doses of tirzepatide) and ≤ 6.5% (5 mg tirzepatide) were not statistically significantly different between tirzepatide and semaglutide 1 mg. The cost per patient to achieve the composite endpoints (HbA1c < 7.0%, ≤ 6.5%, or < 5.7%/weight loss ≥ 10%/no hypoglycemia) was statistically significantly lower for all doses of tirzepatide than for semaglutide 1 mg. The NNTs for all doses of tirzepatide were statistically significantly lower than that for semaglutide 1 mg to achieve all individual and composite endpoints, with the exception of the 5 mg dose for HbA1c < 7.0% and HbA1c ≤ 6.5%, where tirzepatide had numerically lower NNTs that were not statistically significant.
Conclusion
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that may offer the potential to achieve stringent glycemic goals, weight loss targets, and composite treatment goals at a lower cost per responder compared to semaglutide 1 mg among people with T2D.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>37770706</pmid><doi>10.1007/s13300-023-01470-w</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3442-1714</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1869-6953 |
| ispartof | Diabetes therapy, 2023-12, Vol.14 (12), p.2045-2055 |
| issn | 1869-6953 1869-6961 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10597950 |
| source | Nexis UK; PubMed Central Free; Springer Nature - SpringerLink Journals - Fully Open Access ; Publicly Available Content (ProQuest) |
| subjects | Antidiabetics Cardiology Comparative analysis Dextrose Diabetes Diabetes therapy Drugstores Economic aspects Endocrinology GLP-1 receptor agonists Glucose Glycosylated hemoglobin Hypoglycemia Insulin Internal Medicine Liraglutide Medicine Medicine & Public Health Original Research Patient compliance Patients Pharmaceutical industry Pharmacy Type 2 diabetes |
| title | Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A45%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20per%20Patient%20Achieving%20Treatment%20Targets%20and%20Number%20Needed%20to%20Treat%20with%20Tirzepatide%20Versus%20Semaglutide%201%C2%A0mg%20in%20Patients%20with%20Type%202%20Diabetes%20in%20the%20United%20States&rft.jtitle=Diabetes%20therapy&rft.au=Mody,%20Reema%20R.&rft.date=2023-12-01&rft.volume=14&rft.issue=12&rft.spage=2045&rft.epage=2055&rft.pages=2045-2055&rft.issn=1869-6953&rft.eissn=1869-6961&rft_id=info:doi/10.1007/s13300-023-01470-w&rft_dat=%3Cgale_pubme%3EA770254159%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-dfaa847ec7b14d6ee2a2c6635a79b202c0848e3119a3c2c32e9bc0f0c38eee6e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2938145740&rft_id=info:pmid/37770706&rft_galeid=A770254159&rfr_iscdi=true |